Work

Challenges and prospects of CSF1R targeting for advanced malignancies.

Year: 2023

Type: article

Abstract: values ≥ 0.08). Concurrent upregulation of ≥ 2 additional immune checkpoint markers (e.g. PD-L1, BTLA, CTLA4, LAG3, TIM3) was observed in all tumor samples with CSF1R expression ≥ 50th percentile. Pending further large prospective studies, patients with high tumor CSF1R expression may need treatment that co-targets the specific immune checkpoint pathways activated in order to impact outcome.

Source: PubMed

Authors: Ann Moeller, Razelle Kurzrock, Gregory P Botta, Jacob J Adashek, Hitendra Patel, Suzanna Lee, Sarabjot Pabla, Mary K Nesline, Jeffrey Conroy, Jason K Sicklick, Shumei Kato

Institutions: Sharp Rees-Stealy Medical Group, Medical College of Wisconsin, WIN Consortium, Medical College of Wisconsin Cancer Center, Moores Cancer Center, Johns Hopkins University, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, UC San Diego Health System, University of California San Diego

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Johns Hopkins University, Western University of Health Sciences, Moores Cancer Center, UC San Diego Health, University of California, San Diego, Sidney Kimmel Comprehensive Cancer Center, Medical College of Wisconsin Cancer Center

OpenAlex ID: W4385716963

FWCI: 1.346

Cites: 23

Cited by: 13

Related to: 10